KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2025)

Historic Receivables for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $1.5 billion.

  • Amneal Pharmaceuticals' Receivables rose 2027.06% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 2027.06%. This contributed to the annual value of $784.9 million for FY2024, which is 3512.96% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Receivables stood at $1.5 billion for Q3 2025, which was up 2027.06% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Receivables ranged from a high of $1.5 billion in Q3 2025 and a low of $531.7 million during Q1 2021
  • In the last 5 years, Amneal Pharmaceuticals' Receivables had a median value of $1.2 billion in 2024 and averaged $1.1 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Receivables tumbled by 6342.42% in 2021 and then skyrocketed by 8446.23% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables (Quarter) stood at $672.4 million in 2021, then increased by 15.26% to $774.9 million in 2022, then soared by 56.13% to $1.2 billion in 2023, then rose by 8.51% to $1.3 billion in 2024, then rose by 11.87% to $1.5 billion in 2025.
  • Its Receivables stands at $1.5 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.3 billion for Q1 2025.